Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (241-250 of 520) with videos related to

Pageof 52
Sort By:
Diabetes Care|July 11, 2022
Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker StudyHertzel C Gerstein, Sibylle Hess, Brian Claggett, et al.
Journal of the American College of Cardiology|February 19, 2013
Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery diseaseTorbjørn Omland, Marc A Pfeffer, Scott D Solomon, et al.
Journal of the American College of Cardiology|July 17, 2007
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE TrialTorbjørn Omland, Marc S Sabatine, Kathleen A Jablonski, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 6, 2021
Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HFThor Ueland, Lars Gullestad, Lei Kou, et al.
The New England Journal of Medicine|April 27, 2017
Spironolactone Metabolites in TOPCAT - New Insights into Regional VariationSimon de Denus, Eileen O'Meara, Akshay S Desai, et al.
European Journal of Heart Failure|May 23, 2026
Cardiovascular events after acute myocardial infarction complicated by low ejection fraction and/or congestion: a landmark analysis of the PARADISE-MI trialJacinthe Boulet, Jean-Lucien Rouleau, Mark Petrie, et al.
European Journal of Heart Failure|January 26, 2022
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HFMaria A Pabón, Jonathan W Cunningham, Brian L Claggett, et al.
European Heart Journal|October 27, 2009
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trialJonathan P Piccini, Min Zhang, Karen Pieper, et al.
Circulation. Heart Failure|March 26, 2013
Right ventricular function, pulmonary pressure estimation, and clinical outcomes in cardiac resynchronization therapyPatricia Campbell, Madoka Takeuchi, Mikhail Bourgoun, et al.
American Heart Journal|April 29, 2006
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialJohn J V McMurray, James B Young, Mark E Dunlap, et al.
Pageof 52

Showing results (241-250 of 520) with videos related to

Sort By:
Pageof 52
Diabetes Care|July 11, 2022
Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker StudyHertzel C Gerstein, Sibylle Hess, Brian Claggett, et al.
Journal of the American College of Cardiology|February 19, 2013
Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery diseaseTorbjørn Omland, Marc A Pfeffer, Scott D Solomon, et al.
Journal of the American College of Cardiology|July 17, 2007
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE TrialTorbjørn Omland, Marc S Sabatine, Kathleen A Jablonski, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 6, 2021
Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HFThor Ueland, Lars Gullestad, Lei Kou, et al.
The New England Journal of Medicine|April 27, 2017
Spironolactone Metabolites in TOPCAT - New Insights into Regional VariationSimon de Denus, Eileen O'Meara, Akshay S Desai, et al.
European Journal of Heart Failure|May 23, 2026
Cardiovascular events after acute myocardial infarction complicated by low ejection fraction and/or congestion: a landmark analysis of the PARADISE-MI trialJacinthe Boulet, Jean-Lucien Rouleau, Mark Petrie, et al.
European Journal of Heart Failure|January 26, 2022
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HFMaria A Pabón, Jonathan W Cunningham, Brian L Claggett, et al.
European Heart Journal|October 27, 2009
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trialJonathan P Piccini, Min Zhang, Karen Pieper, et al.
Circulation. Heart Failure|March 26, 2013
Right ventricular function, pulmonary pressure estimation, and clinical outcomes in cardiac resynchronization therapyPatricia Campbell, Madoka Takeuchi, Mikhail Bourgoun, et al.
American Heart Journal|April 29, 2006
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialJohn J V McMurray, James B Young, Mark E Dunlap, et al.
Pageof 52